Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.60 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.48 |
| ▸ | CMA1 | P23946 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209394 | 1.00 | MALT1 (0.60) | MALT1EPHA2CMA1ELANEOPRM1 | |
| SCHEMBL22209365 | 0.94 | MALT1 (0.64) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL18621052 | 0.94 | MALT1 (0.64) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL22811073 | 0.94 | MALT1 (0.64) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL18619572 | 0.94 | MALT1 (0.64) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL19019831 | 0.93 | MALT1 (0.52) | MALT1EPHA2CMA1ELANEOPRM1 | |
| SCHEMBL22209378 | 0.92 | MALT1 (0.61) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL18619579 | 0.92 | MALT1 (0.61) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL22209379 | 0.92 | MALT1 (0.61) | MALT1EPHA2CMA1ELANE | |
| SCHEMBL22209464 | 0.90 | MALT1 (0.57) | MALT1EPHA2CMA1ELANEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-27 | — | — | US | disclosed |
| US-11571427-B2 | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | CD47, ICOS, LCK | MALT1 133/4885EPHA2 1130/4885CMA1 2943/4885 |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, CD274, TP53 | MALT1 1/4885EPHA2 2056/4885CMA1 1456/4885 |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | MALT1 1/4885EPHA2 4242/4885CMA1 130/4885 |
| US-11571427-B2 | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment | CD47, ICOS, LCK | MALT1 133/4885EPHA2 1130/4885CMA1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.